Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Research Partnership

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Research Partnership

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

Bristol-Myers Squibb (BMS) building

Positive data for BMS’ clazakizumab in arthritis

Phase II results indicate drug is as effective as AbbVie’s Humira

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

- PMLiVE

Isis drops arthritis candidate

ISIS-CRP Rx disappoints in phase II

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

- PMLiVE

FDA approves intravenous Simponi for arthritis treatment

J&J says Simponi Aria will offer less frequent dosing schedule than subcutaneous version

- PMLiVE

Pfizer wins Xeljanz approvals in five more countries

Switzerland, Argentina, Kuwait, United Arab Emirates and Russia to receive arthritis drug

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links